Braidwell LP Buys Shares of 681,182 Dyne Therapeutics, Inc. (NASDAQ:DYN)

Braidwell LP acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 681,182 shares of the company's stock, valued at approximately $16,049,000. Braidwell LP owned about 0.67% of Dyne Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in DYN. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after buying an additional 721 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Dyne Therapeutics in the 4th quarter worth approximately $257,000. Magnetar Financial LLC bought a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $263,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after acquiring an additional 1,249 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Trading Up 1.2 %

DYN stock traded up $0.14 during midday trading on Friday, hitting $11.44. The company had a trading volume of 4,515,955 shares, compared to its average volume of 1,647,259. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -3.21 and a beta of 1.19. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The stock's 50 day moving average price is $10.37 and its 200 day moving average price is $18.07.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. 14.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

DYN has been the subject of several research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. HC Wainwright decreased their price objective on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday. Piper Sandler lowered their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.85.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.